Actinium-225 DOTATATE Chelation for Neuroendocrine Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuroendocrine tumors, particularly lung carcinoids, are limited in efficacy and often lead to relapse, with existing beta-particle emitting radiopharmaceuticals like 177Lu-DOTATATE showing stabilization but not complete eradication of disease, and alpha-particle emitting therapies offering potential but requiring improved preparation methods.
Innovation Solution
Development of processes for preparing alpha-emitting radiopharmaceutical compositions, specifically DOTATATE chelates with Actinium-225, allowing for secular equilibrium before administration to enhance treatment efficacy and stability, thereby improving targeting and minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If beta-particle emitting radiopharmaceuticals like 177Lu-DOTATATE are used for treatment, then tumor stabilization is achieved, but complete eradication of disease is not accomplished and relapse occurs
Solution Approach 1:
The patent transitions from beta-particle emitting radionuclides (177Lu) to alpha-particle emitting radionuclides (225Ac), changing the fundamental physical parameter of radiation type. Alpha particles have higher linear energy transfer and shorter range, providing more potent cytotoxic effects for complete tumor eradication while maintaining targeted delivery through the same DOTATATE ligand
2Productivity
If alpha-particle emitting radionuclides are used for therapy, then complete tumor eradication is achieved, but preparation complexity increases and secular equilibrium must be waited
Solution Approach 1:
The patent performs the chelation of DOTATATE to the alpha-emitting radionuclide (225Ac) in advance, creating a stable radiopharmaceutical complex before administration. This preliminary action allows the system to reach secular equilibrium beforehand, simplifying the clinical administration process while maintaining the therapeutic benefits of alpha-particle emission
3Reliability
If alpha-particle emitting radiopharmaceuticals are administered, then tumor targeting is improved, but toxicity management becomes more challenging
Solution Approach 1:
The patent utilizes the short range and high linear energy transfer of alpha particles to concentrate cytotoxic effects locally within the tumor tissue. The DOTATATE ligand provides selective binding to somatostatin receptors on tumor cells, ensuring that the harmful alpha radiation is delivered precisely to the target site while minimizing exposure to surrounding healthy tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The alpha-emitting radiopharmaceutical compositions, such as 225Ac-DOTATATE, demonstrate improved tumor targeting with reduced toxicity and enhanced stability, leading to effective treatment of neuroendocrine tumors by achieving significant tumor growth inhibition and prolonged progression-free survival.
Implementation Method 1
Actinium-225 (225Ac) is an α-particle emitting isotope that has demonstrated significant utility in systemic targeted radionuclide therapy and decays with a 10-day half-life via a complex decay scheme, emitting four a particles
Implementation Method 2
processes for the preparation of DOTATATE chelates of alpha emitting radionuclides
Data Source
AI summary
The present disclosure provides processes for the preparation of alpha emitting radiopharmaceutical compositions, in particular DOTATATE complexes of alpha emitting radionuclides, as well as use of such prepared compositions in the treatment of cancers.